Enhancing ADCs Within and Outside the Tumor With Sutro’s Platform Technologies Leads to a Higher Therapeutic Index

Sutro’s ADC platform is uniquely powered by a proprietary, cell-free extract protein expression system, enabling high-quality biotherapeutic manufacturing with key advantages over mammalian cell-based systems. In patients, only ~1% of ADCs administered bind to tumor antigens, leaving most to circulate and accumulate in healthy tissues, resulting in platform toxicities that limit clinical dosing. Sutro’s platform-integrated ADC technologies have significantly mitigated these toxicities, achieving up to 50-fold higher exposure levels in preclinical safety studies compared to approved, conventional ADCs. Addressing the urgent need for more effective cancer therapies, Sutro is advancing dual-payload ADCs designed to deliver agents with distinct mechanisms of action, improving intratumoral efficacy and clinical durability. Preclinical results with dual-payload ADCs combining Topo1 and MMAE demonstrate deeper, more sustained anti-tumor responses than conventional single-payload ADCs. Overall, Sutro’s platform and manufacturing innovations enhance the safety, efficacy, and therapeutic index of ADCs significantly, supporting the development of next-generation oncology treatments.

Dr. Hans-Peter Gerber brings 30 years of oncology R&D experience, specializing in antibody-drug conjugates (ADCs), redirected T-cell targeting compounds (bispecifics), and adoptive T-cell therapies (TCR-T, CAR-T). He has overseen multiple successful programs across pharma, biotech, and startups, contributing to 6 of the 15 approved ADCs and more than 10 IND filings, including Avastin, Mylotarg, and Besponsa.

He joined Sutro Biopharma in 2023 as CSO, leading a team of 80 scientists. In 2022, he co-founded Codeable Therapeutics, advancing next-generation ADCs, and secured seed funding in 2023. Hans-Peter is also Chairman of T-CURX, a CAR-T startup in Germany, and serves on the board of Athebio in Switzerland, focused on Darpin-based therapeutics.

From 2018–2022, he was CSO and SVP at 3T Biosciences, where he expanded R&D, raised over $50M, and served as interim CEO. He previously led R&D at Maverick Therapeutics, acquired by Takeda, and served as an independent director at NBE Therapeutics, acquired by Boehringer Ingelheim. Earlier roles at Genentech, Seattle Genetics, and Pfizer included leadership of oncology biologics and ADC development.

An internationally recognized oncology leader, Hans-Peter has authored 100+ papers and holds 100+ patents. He earned his MS and PhD at the University of Zurich, Switzerland.

Registration: https://us06web.zoom.us/webinar/register/WN_ozMGXdOpTY2TdJnF37hrwg#/registration